EnglishChronic beryllium disease (CBD) is a lung disorder related to beryllium exposure and is characterized by the accumulation in the lung of beryllium-specific CD4+ major histocompatibility complex (MHC) class II-restricted T lymphocytes. Evaluation of MHC class II genes in 33 CBD cases and 44 controls has shown a negative association with HLA-DPB1*0401 (P < 0.001) and a positive association with HLA-DPB1*0201 (P < 0.05) alleles, which differ at residues 36, 55 to 56, and 69 of the beta1 chain. Among CBD cases, 97 percent expressed the HLA-DPB1*0201-associated glutamic acid (unaffected population, 30 percent; P < 0.001) at residue 69, a position involved in susceptibility to autoimmune disorders. This suggests that HLA-DP has a role in conferring susceptibility and that residue 69 of HLA-DPB1 could be used in risk assessment for CBD.
HLA-DPB1 Glutamate 69: a genetic marker of beryllium disease / Richeldi, Luca; R., Sorrentino; C., Saltini. - In: SCIENCE. - ISSN 0036-8075. - STAMPA. - 262(1993), pp. 242-244.
| Data di pubblicazione: | 1993 |
| Titolo: | HLA-DPB1 Glutamate 69: a genetic marker of beryllium disease |
| Autore/i: | Richeldi, Luca; R., Sorrentino; C., Saltini |
| Autore/i UNIMORE: | |
| Rivista: | |
| Volume: | 262 |
| Pagina iniziale: | 242 |
| Pagina finale: | 244 |
| Codice identificativo ISI: | WOS:A1993MA66500035 |
| Codice identificativo Scopus: | 2-s2.0-0027430877 |
| Codice identificativo Pubmed: | 8105536 |
| Citazione: | HLA-DPB1 Glutamate 69: a genetic marker of beryllium disease / Richeldi, Luca; R., Sorrentino; C., Saltini. - In: SCIENCE. - ISSN 0036-8075. - STAMPA. - 262(1993), pp. 242-244. |
| Tipologia | Articolo su rivista |
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
Copyright © 2020